Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HepaSphere's targeted chemo:

This article was originally published in Clinica

Executive Summary

BioSphere Medical has CE-marked its doxorubicin-impregnated microspheres for sale in Europe under the name HepaSphere. The product will be used for the transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC). As a condition of the approval, BioSphere will conduct a multicentre European post-marketing registry in 100 patients. Standard TACE involves injection of a concentrated dose of a chemotherapeutic, such as doxorubicin, directly into the blood vessels supplying a tumour, followed by the infusion of an embolic agent into these blood vessels, thus blocking its blood supply. The blocked vessels force the chemotherapeutic into direct contact with the tumour and minimise side-effects. TACE using HepaSphere loaded with doxorubicin further concentrates the chemotherapeutic effect by embolising the target tissue better and delivering the drug over an extended time frame, Rockland, Massachusetts-based BioSphere claims.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel